Brendan McMullan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Brendan McMullan has a total of 271 co-authors. Here are the top co-authors by number of shared publications:
- Philip Britton
Sydney Infectious Diseases Institute, Faculty of Medicine and Health, The University of Sydney B ,
10 shared publications - Christopher C. Blyth
University of Western Australia
7 shared publications - Adam William Bartlett
Kirby Institute, University of New South Wales, Sydney, Australia
5 shared publications - Annaleise R. Howard-Jones
Sydney Institute for Infectious Diseases, University of Sydney, Camperdown, Australia
5 shared publications - Julia Elizabeth Clark
Department of Infectious Diseases Queensland Children's Hospital Brisbane Queensland Australia
4 shared publications Lisa Hall
CNational Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia
4 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (6)
Contextualizing a One Health definition of appropriate antimicrobial use
Background and objectives: Antimicrobial stewardship initiatives are designed to improve the appropriateness of antimicrobial use and thereby maximize benefits and minimize risks. Currently, there is no shared understanding of appropriate use. Qualitative research with key stakeholders in human and animal health is critical to inform a One Health definition and to support global stewardship efforts. Methods: Four qualitative focus groups were held in 2024 with livestock producers, consumers, healthcare professionals and policymakers to examine factors affecting antimicrobial use and stewardship. A thematic analysis methodology informed by grounded theory was adopted, capturing themes as they emerged directly from the data. Results: Thematic analysis identified two themes:Structural and economic barriers; in animal health, consumer demand for free-range or antibiotic-free produce conflicted with practical antimicrobial use. This was compounded by differences between large and small livestock enterprises and regulatory constraints around off-label antimicrobial use. In human health, time pressure, limited access to review appointments and conflicting consumer–prescriber expectations influenced antimicrobial decision-making.Information access and education; participants identified gaps in antimicrobial stewardship education for livestock producers, limited public understanding of appropriate use and underused communication channels to support consistent context-specific messaging. Conclusion: This study highlights how participants understood appropriate antimicrobial use across One Health sectors and the structural, economic, informational and educational factors they perceived as shaping whether it could be achieved in practice. Establishing contextualized, consensus definitions is essential for measuring prescribing quality, benchmarking practice and targeting stewardship interventions. These findings will inform an international Delphi process to develop practical, implementable One Health definitions of appropriate use.
- 31 October 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (6)
Open AccessContextualizing a One Health definition of appropriate antimicrobial use
Background and objectives: Antimicrobial stewardship initiatives are designed to improve the appropriateness of antimicrobial use and thereby maximize benefits and minimize risks. Currently, there is no shared understanding of appropriate use. Qualitative research with key stakeholders in human and animal health is critical to inform a One Health definition and to support global stewardship efforts. Methods: Four qualitative focus groups were held in 2024 with livestock producers, consumers, healthcare professionals and policymakers to examine factors affecting antimicrobial use and stewardship. A thematic analysis methodology informed by grounded theory was adopted, capturing themes as they emerged directly from the data. Results: Thematic analysis identified two themes:Structural and economic barriers; in animal health, consumer demand for free-range or antibiotic-free produce conflicted with practical antimicrobial use. This was compounded by differences between large and small livestock enterprises and regulatory constraints around off-label antimicrobial use. In human health, time pressure, limited access to review appointments and conflicting consumer–prescriber expectations influenced antimicrobial decision-making.Information access and education; participants identified gaps in antimicrobial stewardship education for livestock producers, limited public understanding of appropriate use and underused communication channels to support consistent context-specific messaging. Conclusion: This study highlights how participants understood appropriate antimicrobial use across One Health sectors and the structural, economic, informational and educational factors they perceived as shaping whether it could be achieved in practice. Establishing contextualized, consensus definitions is essential for measuring prescribing quality, benchmarking practice and targeting stewardship interventions. These findings will inform an international Delphi process to develop practical, implementable One Health definitions of appropriate use.
- Open Access
- 5 August 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (10) , 1901-1906
HOMEFREE : Scaling‐Up Evidence‐Based Guidelines for IV ‐to‐Oral Antibiotic Switch in Hospitalised Children, an Implementation Study Protocol
Background: Around half of children admitted to hospital receive intravenous ( IV ) antibiotics, contributing to higher costs, vascular access complications and longer hospital stays. A single‐site pilot in a tertiary Australian paediatric hospital implemented nationally endorsed Australasian Stewardship of Antimicrobials in Paediatrics ( ANZPID ‐ ASAP ) IV ‐to‐oral antibiotic switch guidelines, improving timely switch rates from 64% to 82%. Following this success, a broader study is planned to assess the feasibility of scaling this approach across hospitals of varying types and sizes within NSW , Australia. Aims: The HOMEFREE study hypothesises that implementation of an IV‐to‐oral antibiotic switch programme based on endorsed guidelines and supported by audit and feedback will increase the proportion of hospitalised children transitioned to oral therapy or antibiotic cessation within 24 h of meeting eligibility criteria. The study will evaluate both effectiveness and implementation feasibility across tertiary paediatric and general hospitals in metropolitan and rural/regional settings. This paper presents the study protocol. Methods: Participating sites will select context‐appropriate interventions to support guideline‐concordant prescribing, informed by shared learning during the prospective phase. Effectiveness will be assessed using prospective audits, with key outcomes including timely guideline‐concordant IV‐to‐oral switch and hospital length of stay. Implementation feasibility will be evaluated using the Consolidated Framework for Implementation Research through surveys of local project committee members conducted before and after 12 months of audit and feedback. Conclusions: This study will assess the effectiveness and feasibility of translating and scaling best‐practice IV‐to‐oral antibiotic switch guidelines for children in real‐world hospital settings.
- 5 August 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (10) , 1901-1906
Open AccessHOMEFREE : Scaling‐Up Evidence‐Based Guidelines for IV ‐to‐Oral Antibiotic Switch in Hospitalised Children, an Implementation Study Protocol
Background: Around half of children admitted to hospital receive intravenous ( IV ) antibiotics, contributing to higher costs, vascular access complications and longer hospital stays. A single‐site pilot in a tertiary Australian paediatric hospital implemented nationally endorsed Australasian Stewardship of Antimicrobials in Paediatrics ( ANZPID ‐ ASAP ) IV ‐to‐oral antibiotic switch guidelines, improving timely switch rates from 64% to 82%. Following this success, a broader study is planned to assess the feasibility of scaling this approach across hospitals of varying types and sizes within NSW , Australia. Aims: The HOMEFREE study hypothesises that implementation of an IV‐to‐oral antibiotic switch programme based on endorsed guidelines and supported by audit and feedback will increase the proportion of hospitalised children transitioned to oral therapy or antibiotic cessation within 24 h of meeting eligibility criteria. The study will evaluate both effectiveness and implementation feasibility across tertiary paediatric and general hospitals in metropolitan and rural/regional settings. This paper presents the study protocol. Methods: Participating sites will select context‐appropriate interventions to support guideline‐concordant prescribing, informed by shared learning during the prospective phase. Effectiveness will be assessed using prospective audits, with key outcomes including timely guideline‐concordant IV‐to‐oral switch and hospital length of stay. Implementation feasibility will be evaluated using the Consolidated Framework for Implementation Research through surveys of local project committee members conducted before and after 12 months of audit and feedback. Conclusions: This study will assess the effectiveness and feasibility of translating and scaling best‐practice IV‐to‐oral antibiotic switch guidelines for children in real‐world hospital settings.
- Open Access
- 28 July 2026
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 73
Impact and effectiveness of Australia's 2025 hybrid RSV immunisation program: results from the PAEDS-FluCAN Network
- 28 July 2026
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 73
Open AccessImpact and effectiveness of Australia's 2025 hybrid RSV immunisation program: results from the PAEDS-FluCAN Network
- Open Access
- 2 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (6) , ofag275
The Evolving Epidemiology of Invasive Pneumococcal Disease in Australian Children: A Multicentre Retrospective Observational Study
Background: In Australia, high pneumococcal conjugate vaccine (PCV) coverage has been achieved, yet invasive pneumococcal disease (IPD) continues to cause a significant burden of disease. The epidemiology of IPD was altered by the nonpharmaceutical interventions (NPIs) used to control the coronavirus disease (COVID-19) pandemic. We aimed to analyze this impact on the clinical characteristics associated with IPD in Australian children. Method: We systematically evaluated the clinical and microbiological characteristics of IPD in children (14 days; 13% vs 1%, P = .001). Conclusions: Alternations in the prevalence of respiratory viral transmission influence the epidemiology and clinical presentation of IPD. Newer PCVs and the implementation of immunization programs that target viral pathogens associated with IPD may reduce the ongoing burden of IPD in children.
- 2 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (6) , ofag275
Open AccessThe Evolving Epidemiology of Invasive Pneumococcal Disease in Australian Children: A Multicentre Retrospective Observational Study
Background: In Australia, high pneumococcal conjugate vaccine (PCV) coverage has been achieved, yet invasive pneumococcal disease (IPD) continues to cause a significant burden of disease. The epidemiology of IPD was altered by the nonpharmaceutical interventions (NPIs) used to control the coronavirus disease (COVID-19) pandemic. We aimed to analyze this impact on the clinical characteristics associated with IPD in Australian children. Method: We systematically evaluated the clinical and microbiological characteristics of IPD in children (14 days; 13% vs 1%, P = .001). Conclusions: Alternations in the prevalence of respiratory viral transmission influence the epidemiology and clinical presentation of IPD. Newer PCVs and the implementation of immunization programs that target viral pathogens associated with IPD may reduce the ongoing burden of IPD in children.
- Open Access
- 16 March 2026
- Published by Elsevier in SSRN Electronic Journal
Impact and Effectiveness of Australia’s 2025 hybrid RSV Immunisation Program: Results from the PAEDS-FluCAN Network
Background: Australia introduced a hybrid Respiratory Syncytial Virus (RSV) Maternal and Infant Protection Program (RSV-MIPP) in 2025, using National Immunisation Program-funded RSV vaccine for pregnant people from 28 weeks' gestation and jurisdiction-funded nirsevimab. We estimated real-world effectiveness and assessed the impact of the RSV-MIPP program across a participating surveillance network.Methods: Thirteen national sentinel PAEDS-FluCAN network hospitals contributed paediatric RSV data. From April 2024 and November 2025, hospitalised children with RSV-associated acute respiratory infection (ARI; cases) and contemporaneous RSV-negative controls were recruited. Immunisation effectiveness was estimated using a test-negative design with multivariable regression, adjusted for prespecified covariates, and calculated as (1−adjusted odds ratio)×100% with 95% confidence intervals (CIs). Impact was assessed as the 2024–2025 change in the cumulative number of RSV hospitalisations during epidemiological weeks 14–48, excluding hospitals in two states with comprehensive 2024 nirsevimab programs, and stratified by age group.Findings: Between 1 January and 31 November 2025, 3743 children were recruited (2719 RSV-positive cases; 1024 test-negative controls). Overall effectiveness against RSV-associated ARI hospitalisation in the RSV-MIPP newborn cohort (born from 17 February) was 82·0% (95% CI: 70·0,89·2). Effectiveness estimates for maternal vaccination and nirsevimab were 80·8% (67·8, 88·6) and 89·5% (73·4, 95·8) respectively. Nirsevimab effectiveness in the catch-up cohort (born 1st October 2024 to 16th February 2025) was 87·3% (63·8, 95·5). The program’s impact was associated with 43·8%, 20·1% and 8·5% reduction in hospitalisations in infants aged 0 to <3months, 3 to <6months and 6 to 12months respectively.Interpretation: These first southern hemisphere estimates of a hybrid RSV prevention program demonstrated high effectiveness against RSV hospitalisation over a single season. Longitudinal evaluation of the RSV-MIPP is needed to understand sustained effectiveness and year-round population level impacts.
- 16 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImpact and Effectiveness of Australia’s 2025 hybrid RSV Immunisation Program: Results from the PAEDS-FluCAN Network
Background: Australia introduced a hybrid Respiratory Syncytial Virus (RSV) Maternal and Infant Protection Program (RSV-MIPP) in 2025, using National Immunisation Program-funded RSV vaccine for pregnant people from 28 weeks' gestation and jurisdiction-funded nirsevimab. We estimated real-world effectiveness and assessed the impact of the RSV-MIPP program across a participating surveillance network.Methods: Thirteen national sentinel PAEDS-FluCAN network hospitals contributed paediatric RSV data. From April 2024 and November 2025, hospitalised children with RSV-associated acute respiratory infection (ARI; cases) and contemporaneous RSV-negative controls were recruited. Immunisation effectiveness was estimated using a test-negative design with multivariable regression, adjusted for prespecified covariates, and calculated as (1−adjusted odds ratio)×100% with 95% confidence intervals (CIs). Impact was assessed as the 2024–2025 change in the cumulative number of RSV hospitalisations during epidemiological weeks 14–48, excluding hospitals in two states with comprehensive 2024 nirsevimab programs, and stratified by age group.Findings: Between 1 January and 31 November 2025, 3743 children were recruited (2719 RSV-positive cases; 1024 test-negative controls). Overall effectiveness against RSV-associated ARI hospitalisation in the RSV-MIPP newborn cohort (born from 17 February) was 82·0% (95% CI: 70·0,89·2). Effectiveness estimates for maternal vaccination and nirsevimab were 80·8% (67·8, 88·6) and 89·5% (73·4, 95·8) respectively. Nirsevimab effectiveness in the catch-up cohort (born 1st October 2024 to 16th February 2025) was 87·3% (63·8, 95·5). The program’s impact was associated with 43·8%, 20·1% and 8·5% reduction in hospitalisations in infants aged 0 to <3months, 3 to <6months and 6 to 12months respectively.Interpretation: These first southern hemisphere estimates of a hybrid RSV prevention program demonstrated high effectiveness against RSV hospitalisation over a single season. Longitudinal evaluation of the RSV-MIPP is needed to understand sustained effectiveness and year-round population level impacts.
- Open Access
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Impact and Effectiveness of Australia's 2025 Hybrid RSV Immunisation Program: Results from the PAEDS-FluCAN Network
Background: Australia introduced a hybrid Respiratory Syncytial Virus (RSV) Maternal and Infant Protection Program (RSV-MIPP) in 2025, using National Immunisation Program-funded RSV vaccine for pregnant people from 28 weeks' gestation and jurisdiction-funded nirsevimab. We estimated real-world effectiveness and assessed the impact of the RSV-MIPP program across a participating surveillance network. Methods: Thirteen national sentinel PAEDS-FluCAN network hospitals contributed paediatric RSV data. From April 2024 and November 2025, hospitalised children with RSV-associated acute respiratory infection (ARI; cases) and contemporaneous RSV-negative controls were recruited. Immunisation effectiveness was estimated using a test-negative design with multivariable regression, adjusted for prespecified covariates, and calculated as (1−adjusted odds ratio)×100% with 95% confidence intervals (CIs). Impact was assessed as the 2024–2025 change in the cumulative number of RSV hospitalisations during epidemiological weeks 14–48, excluding hospitals in two states with comprehensive 2024 nirsevimab programs, and stratified by age group. Findings: Between 1 January and 31 November 2025, 3743 children were recruited (2719 RSV-positive cases; 1024 test-negative controls). Overall effectiveness against RSV-associated ARI hospitalisation in the RSV-MIPP newborn cohort (born from 17 February) was 82·0% (95% CI: 70·0,89·2). Effectiveness estimates for maternal vaccination and nirsevimab were 80·8% (67·8, 88·6) and 89·5% (73·4, 95·8) respectively. Nirsevimab effectiveness in the catch-up cohort (born 1st October 2024 to 16th February 2025) was 87·3% (63·8, 95·5). The program’s impact was associated with 43·8%, 20·1% and 8·5% reduction in hospitalisations in infants aged 0 to <3months, 3 to <6months and 6 to 12months respectively. Interpretation: These first southern hemisphere estimates of a hybrid RSV prevention program demonstrated high effectiveness against RSV hospitalisation over a single season. Longitudinal evaluation of the RSV-MIPP is needed to understand sustained effectiveness and year-round population level impacts. Funding: This work was sponsored by the Australian Government Department of Health, Disability and Ageing.
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImpact and Effectiveness of Australia's 2025 Hybrid RSV Immunisation Program: Results from the PAEDS-FluCAN Network
Background: Australia introduced a hybrid Respiratory Syncytial Virus (RSV) Maternal and Infant Protection Program (RSV-MIPP) in 2025, using National Immunisation Program-funded RSV vaccine for pregnant people from 28 weeks' gestation and jurisdiction-funded nirsevimab. We estimated real-world effectiveness and assessed the impact of the RSV-MIPP program across a participating surveillance network. Methods: Thirteen national sentinel PAEDS-FluCAN network hospitals contributed paediatric RSV data. From April 2024 and November 2025, hospitalised children with RSV-associated acute respiratory infection (ARI; cases) and contemporaneous RSV-negative controls were recruited. Immunisation effectiveness was estimated using a test-negative design with multivariable regression, adjusted for prespecified covariates, and calculated as (1−adjusted odds ratio)×100% with 95% confidence intervals (CIs). Impact was assessed as the 2024–2025 change in the cumulative number of RSV hospitalisations during epidemiological weeks 14–48, excluding hospitals in two states with comprehensive 2024 nirsevimab programs, and stratified by age group. Findings: Between 1 January and 31 November 2025, 3743 children were recruited (2719 RSV-positive cases; 1024 test-negative controls). Overall effectiveness against RSV-associated ARI hospitalisation in the RSV-MIPP newborn cohort (born from 17 February) was 82·0% (95% CI: 70·0,89·2). Effectiveness estimates for maternal vaccination and nirsevimab were 80·8% (67·8, 88·6) and 89·5% (73·4, 95·8) respectively. Nirsevimab effectiveness in the catch-up cohort (born 1st October 2024 to 16th February 2025) was 87·3% (63·8, 95·5). The program’s impact was associated with 43·8%, 20·1% and 8·5% reduction in hospitalisations in infants aged 0 to <3months, 3 to <6months and 6 to 12months respectively. Interpretation: These first southern hemisphere estimates of a hybrid RSV prevention program demonstrated high effectiveness against RSV hospitalisation over a single season. Longitudinal evaluation of the RSV-MIPP is needed to understand sustained effectiveness and year-round population level impacts. Funding: This work was sponsored by the Australian Government Department of Health, Disability and Ageing.
- 1 November 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (5) , 1309-1317
Clinical Characteristics and In-hospital Outcomes Associated With Respiratory Syncytial Virus vs Other Viral Acute Lower Respiratory Infections in Hospitalized Children Younger Than 2 Years
Background: Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infection (ALRI)–associated hospitalizations in children. It is unclear if hospitalized RSV-positive ALRI is clinically different from other viral ALRIs. We aimed to compare the disease impact of hospitalized RSV with other viral ALRI in children aged 2 days; adjusted prevalence ratio, 1.95; 95% CI, 1.14–3.36). However, there were no differences in the need for intensive care or respiratory support. Conclusions: Children with RSV-positive ALRI exhibited more severe symptoms, received more antibiotics, and had longer hospital stays as compared with those with other viral ALRIs, underscoring the need for effective prevention and treatment strategies for RSV.
- 1 November 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (5) , 1309-1317
Clinical Characteristics and In-hospital Outcomes Associated With Respiratory Syncytial Virus vs Other Viral Acute Lower Respiratory Infections in Hospitalized Children Younger Than 2 Years
Background: Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infection (ALRI)–associated hospitalizations in children. It is unclear if hospitalized RSV-positive ALRI is clinically different from other viral ALRIs. We aimed to compare the disease impact of hospitalized RSV with other viral ALRI in children aged 2 days; adjusted prevalence ratio, 1.95; 95% CI, 1.14–3.36). However, there were no differences in the need for intensive care or respiratory support. Conclusions: Children with RSV-positive ALRI exhibited more severe symptoms, received more antibiotics, and had longer hospital stays as compared with those with other viral ALRIs, underscoring the need for effective prevention and treatment strategies for RSV.
- 3 July 2024
- Published by BMJ in Archives of Disease in Childhood - Education & Practice Edition
- Vol. 110 (2) , 64-69
Treatment of toxic shock in children
Toxic shock syndrome (TSS) is a life-threatening complication of infection typically caused by one of two bacterial species: Staphylococcus aureus and Streptococcus pyogenes. The outcomes in children with TSS can be devastating. Careful consideration of TSS is required as a potential differential diagnosis of children presenting with sepsis or severe illness associated with fever and rash.
- 3 July 2024
- Published by BMJ in Archives of Disease in Childhood - Education & Practice Edition
- Vol. 110 (2) , 64-69
Treatment of toxic shock in children
Toxic shock syndrome (TSS) is a life-threatening complication of infection typically caused by one of two bacterial species: Staphylococcus aureus and Streptococcus pyogenes. The outcomes in children with TSS can be devastating. Careful consideration of TSS is required as a potential differential diagnosis of children presenting with sepsis or severe illness associated with fever and rash.
- Open Access
- 27 June 2024
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 62 (6)
Eumycetoma causative agents: A systematic review to inform the World Health Organization priority list of fungal pathogens
The World Health Organization, in response to the growing burden of fungal disease, established a process to develop a fungal priority pathogens list. This systematic review aimed to evaluate the epidemiology and impact of eumycetoma. PubMed and Web of Science were searched to identify studies published between 1 January 2011 and 19 February 2021. Studies reporting on mortality, inpatient care, complications and sequelae, antifungal susceptibility, risk factors, preventability, annual incidence, global distribution, and emergence during the study time frames were selected. Overall, 14 studies were eligible for inclusion. Morbidity was frequent with moderate to severe impairment of quality of life in 60.3%, amputation in up to 38.5%, and recurrent or long-term disease in 31.8%–73.5% of patients. Potential risk factors included male gender (56.6%–79.6%), younger age (11–30 years; 64%), and farming occupation (62.1%–69.7%). Mycetoma was predominantly reported in Sudan, particularly in central Sudan (37%–76.6% of cases). An annual incidence of 0.1/100 000 persons and 0.32/100 000 persons/decade was reported in the Philippines and Uganda, respectively. In Uganda, a decline in incidence from 3.37 to 0.32/100 000 persons between two consecutive 10-year periods (2000–2009 and 2010–2019) was detected. A community-based, multi-pronged prevention programme was associated with a reduction in amputation rates from 62.8% to 11.9%. With the pre-specified criteria, no studies of antifungal drug susceptibility, mortality, and hospital lengths of stay were identified. Future research should include larger cohort studies, greater drug susceptibility testing, and global surveillance to develop evidence-based treatment guidelines and to determine more accurately the incidence and trends over time.
- 27 June 2024
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 62 (6)
Open AccessEumycetoma causative agents: A systematic review to inform the World Health Organization priority list of fungal pathogens
The World Health Organization, in response to the growing burden of fungal disease, established a process to develop a fungal priority pathogens list. This systematic review aimed to evaluate the epidemiology and impact of eumycetoma. PubMed and Web of Science were searched to identify studies published between 1 January 2011 and 19 February 2021. Studies reporting on mortality, inpatient care, complications and sequelae, antifungal susceptibility, risk factors, preventability, annual incidence, global distribution, and emergence during the study time frames were selected. Overall, 14 studies were eligible for inclusion. Morbidity was frequent with moderate to severe impairment of quality of life in 60.3%, amputation in up to 38.5%, and recurrent or long-term disease in 31.8%–73.5% of patients. Potential risk factors included male gender (56.6%–79.6%), younger age (11–30 years; 64%), and farming occupation (62.1%–69.7%). Mycetoma was predominantly reported in Sudan, particularly in central Sudan (37%–76.6% of cases). An annual incidence of 0.1/100 000 persons and 0.32/100 000 persons/decade was reported in the Philippines and Uganda, respectively. In Uganda, a decline in incidence from 3.37 to 0.32/100 000 persons between two consecutive 10-year periods (2000–2009 and 2010–2019) was detected. A community-based, multi-pronged prevention programme was associated with a reduction in amputation rates from 62.8% to 11.9%. With the pre-specified criteria, no studies of antifungal drug susceptibility, mortality, and hospital lengths of stay were identified. Future research should include larger cohort studies, greater drug susceptibility testing, and global surveillance to develop evidence-based treatment guidelines and to determine more accurately the incidence and trends over time.
- 2 April 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (7) , e235-e239
Challenging Dogma in the Treatment of Childhood Infections: Oral Antibiotics and Shorter Durations
- 2 April 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (7) , e235-e239
Challenging Dogma in the Treatment of Childhood Infections: Oral Antibiotics and Shorter Durations